108 related articles for article (PubMed ID: 23738855)
1. Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
Northcott MJ; Ong WL; Walsh M; McCarthy P; Belleli D; Tran H; Street A; Kemp W; Davis AK
Haemophilia; 2013 Nov; 19(6):847-52. PubMed ID: 23738855
[TBL] [Abstract][Full Text] [Related]
2. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C--an update.
Holmes J; Thompson A; Bell S
Aust Fam Physician; 2013 Jul; 42(7):452-6. PubMed ID: 23826595
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
Craxì A; Piccinino F; Ciancio A; Iannacone C; Deodato B; Golotta C; Ascione A
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):388-95. PubMed ID: 24569819
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
Katsarou O; Theodosiades G; Ioannidou P; Nomikou E; Tsevrenis B; Kouraba A; Deutch M; Terpos E; Dourakis S; Karafoulidou A
Acta Haematol; 2008; 120(2):63-9. PubMed ID: 18827474
[TBL] [Abstract][Full Text] [Related]
7. [Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].
Liu SD; Cheng ML; Ren H; Yang QK; Shu DY
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):589-92. PubMed ID: 23207152
[TBL] [Abstract][Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
9. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH
Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880
[TBL] [Abstract][Full Text] [Related]
10. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
[TBL] [Abstract][Full Text] [Related]
11. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
12. Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection
Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
[TBL] [Abstract][Full Text] [Related]
13. [Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection].
Maksimova SL; Ivanova LM; Kravchenko AV; Serebrovskaia LV; Ol'shanskiĭ AIa; Morgunova NM; Iushchuk ND
Ter Arkh; 2007; 79(11):40-4. PubMed ID: 18219972
[TBL] [Abstract][Full Text] [Related]
14. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
15. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
Hofer H; Aydin I; Neumueller-Guber S; Mueller C; Scherzer TM; Staufer K; Steindl-Munda P; Wrba F; Ferenci P
J Viral Hepat; 2011 Jul; 18(7):513-7. PubMed ID: 20565572
[TBL] [Abstract][Full Text] [Related]
17. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
18. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience.
Posthouwer D; Fischer K; De Heusden N; Mauser-Bunschoten EP
Haemophilia; 2007 Jan; 13(1):98-103. PubMed ID: 17212733
[TBL] [Abstract][Full Text] [Related]
20. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
